MONOFILAMENT MANUFACTURER P V D F F I L A M E N T E X T R U S I O N • Reduce or eradicate die build-up • Improve predictive and final part quality • Optimize PVDF extrusion for the desired coefficient of friction (CoF) • Reduce energy consumption • Boosted overall production efficiency by minimizing die build-up through use of a PVDF-specific processing aid • Achieved a flawless surface by reducing friction and improving flow for enhanced final part quality • Controlled extrusion pressure to reduce energy required in processing Colorant Chromatics PVDF Processing Aid KEY REQUIREMENTS WHY AVIENT?

D is t. ) K W R P P G A V Y F U L R P M G C P H X L F M C H U N IF F E C L A S H K R A E M N C E S C L A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of July 28, 2021 Avient reflects 2021 estimated revenue of $4,650M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 81% Median: 78% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $580M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of July 28, 2021 87 90 86 82 80 78 73 87 82 82 79 79 78 78 77 76 71 67 46 A vi en t K W R P P G A V Y F U L R P M G C P F M C U N V R C E IF F A S H E C L B N R E M N H X L H U N K R A S C L A L B (6) Source: Peer data per Bloomberg market data as of July 28, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 25 Avient reflects 2021 estimated EBITDA of $580M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 18.5 15.1 15.1 14.0 11.0 10.4 29.5 28.2 23.9 18.7 12.4 12.2 11.1 9.3 9.2 9.2 7.6 7.6 6.0 A vi en t K W R P P G A V Y R P M F U L G C P A L B H X L E C L IF F F M C B N R A S H S C L E M N U N V R K R A C E H U N Median: 11.1xMedian: 14.6x SUMMARY: WHY INVEST IN AVIENT?

INVESTMENT IN COMMERCIAL RESOURCES D R I V E S I N N O VAT I V E P R O D U C T P O R T F O L I O AN D S AL E S G R O W T H 2.6x TARGET NET LEVERAGE BY 2021 ~$1Bn REPURCHASED OVER LAST 10 YEARS ~$350MM PAID OVER LAST 10 YEARS RETURNING VALUE TO SHAREHOLDERS 12 Free Cash Flow Dividends Share Repurchases Deleveraging Strong track record of cash generation put to work in M&A and return to shareholders while modestly levered 0.16 0.20 0.26 0.34 0.42 0.50 0.58 0.72 0.79 0.81 11 12 13 14 15 16 17 18 19 20 0.1 0.1 0.2 0.5 0.6 0.7 0.8 0.9 0.9 1.0 11 12 13 14 15 16 17 18 19 20 3.1x 2.6x 2020PF* 2021E Growing Dividend Cumulative Buybacks Net Leverage $B n $ p e r sh ar e *2020 estimate and Pro forma for acquisition of the Clariant Masterbatch business Cash Generation 19 160 240 2011 2019 2020E ~$240MM Another unique value creation lever at Avient is synergy capture with our recent acquisition of Clariant Masterbatch. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 17 Median: 3% Median: 5% Capex / Revenue 2021E (%) Source: Capital IQ market data as of August 24, 2020 AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 83 86 85 84 80 56 89 83 82 82 78 76 76 75 71 70 68 63 61 58 14 A vi en t K W R R P M P P G F U L G C P F M C IF F U N V R B N R H X L E C L E M N F O E A S H C E G R A K R A H U N S C L A L B Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Source: Capital IQ market data as of August 24, 2020 Median: 84% Median: 75% HIGH FREE CASH FLOW CONVERSION 3.1x 2.6x 0.5x 1.9x 2.8x 3.1x 4.5x -0.1x 1.8x 1.9x 2.2x 2.3x 2.4x 2.9x 3.0x 3.0x 3.2x 3.4x 3.4x 3.8x 3.9x 4.8x A vi en t ( 20 P F ) A vi en t ( 21 E ) G C P P P G R P M K W R F U L S C L B N R H U N E C L C E F M C A S H H X L E M N G R A A L B IF F U N V R K R A F O E Net Debt / 2021E EBITDA (1) We typically operate at 2.5–3.0x net debt to EBITDA.

D is t. ) K W R R P M P P G A V Y F U L G C P IF F H X L F M C F O E H U N E C L K R A E M N A S H C E S C L G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of April 27, 2021 Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 20 Avient reflects 2021 estimated EBITDA of $560M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 10.2 17.7 16.0 14.9 14.6 11.6 11.1 26.7 24.0 22.8 14.3 12.7 11.5 11.2 11.1 11.0 10.3 10.1 9.5 9.4 8.3 7.0 A vi en t K W R A V Y R P M P P G G C P F U L A L B H X L E C L IF F F M C B N R A S H G R A F O E S C L E M N U N V R C E K R A H U N Median: 11.1xMedian: 14.8x SUMMARY: WHY INVEST IN AVIENT?

EPS (1) $0.14 $2.67 $3.04 2006 2018 2022PF TOP-TIER SUSTAINABILITY PERFORMANCE AND RECOGNITION Industry Sustainability Standards 90th percentile 84th ESG Ratings Performance 3 1 4 10 PEOPLE C U L T U R E I S E V E R Y T H I N G Community Service 7x Safer than Industry Average World-Class Safety Leadership Development Over $17 million raised since 2010 Diversity & Inclusion 11 2022 RE SU LT S Q4 EBITDA BRIDGE (PRO FORMA TOTAL COMPANY) 13 $ millions CAI: Price / Mix 42 Inflation (20) SEM: Price / Mix 14 Inflation (10) Net Price Benefit 26 Wage and Energy Inflation (13) Clariant Color Integration Synergies 4 Incentives, Other Employee Costs 21 FX (10) Q4 2022 $107 Adjusted EBITDA Q4 2021 $ 132 Demand (50) Russia Import Sales (3) • Demand contraction especially prevalent in EMEA and Asia • Pricing continues to cover inflation of raw materials, wages and energy PROVEN TRACK RECORD OF STRONG AND IMPROVING FREE CASH FLOW GENERATION 14 • Periods of economic weakness have driven higher levels of cash generation due to working capital management • Anticipate continued strong free cash flow generation and conversion despite global uncertainty 78% 78% 80% 80% 81% 78% 84% 83% 80% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 2014 2015 2016 2017 2018 2019 2020 2021 2022 0 50 100 150 200 250 300 350 400 F re e C as h F lo w C o n ve rs io n F re e C as h F lo w FCF $ AVNT FCF Conversion % S&P FCF Conversion % Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA. 2020 is pro forma for Clariant Color and 2022 is pro forma for Avient Protective Materials. $600 $592 2021 2022 $3.02 $3.04 2021 2022 FULL YEAR 2022 PERFORMANCE (TOTAL COMPANY PRO FORMA) 15 Sales Adjusted EBITDA $3,712 $3,653 2021 2022 -2% Adjusted EPS -1% + 1% (in millions) (in millions) (+4% excluding FX) (+5% excluding FX) (+9% excluding FX) FULL YEAR 2022 SEGMENT PERFORMANCE 16 CAI $2,402 $2,355 Sales ($ in millions) $409 $402 EBITDA SEM Pro Forma $1,308 $1,300 Sales $278 $272 EBITDA (+4% excluding FX) - 2% -1% (+5% excluding FX) - 2% (+4% excluding FX) - 2% (+2% excluding FX) PRO FORMA FULL YEAR EPS BRIDGE 17 Pro Forma 2021 Adjusted EPS 3.02$ Foreign Currency (0.23) Russia Import Sales (0.07) Outdoor High Performance (0.13) Color, Additives and Inks 0.18 Specialty Engineered Materials 0.24 Corporate Costs / Other 0.03 Pro Forma 2022 Adjusted EPS 3.04$ FULL YEAR EBITDA BRIDGE (PRO FORMA TOTAL COMPANY) 18 $ millions CAI: Price / Mix 247 Inflation (176) SEM: Price / Mix 121 Inflation (77) Net Price Benefit 115 Wage and Energy Inflation (47) Clariant Color Integration Synergies 23 Incentives, Other Employee Costs 43 FX (34) Full Year 2022 $592 Adjusted EBITDA Full Year 2021 $ 600 Demand (99) Russia Import Sales (9) • Demand primarily impacted by China lockdowns, 4th quarter industrywide destocking and declining consumer sentiment • Pricing outpaced inflation of raw materials, wages and energy 2023 G U IDA N CE $125 $530 Q1 FY $0.55 $2.40 Q1 FY 2023 GUIDANCE 20 Sales Adjusted EBITDA $845 $3,450 Q1 FY Adjusted EPS (in millions) (in millions) CASH FLOW / BALANCE SHEET 21 • IT investment to further integrate acquired businesses and capture operational efficiencies • Restructuring actions to streamline operations and improve profitability, primarily in Europe ($ millions) 2023E Cash Flow from Operating Activities 350$ Less: Run-Rate CapEx (110) CapEx for IT System Upgrade (25) CapEx for Restructuring (15) Total CapEx (150) Free Cash Flow 200$ Adjusted EBITDA 530$ Net Debt / Adjusted EBITDA 2.9x K E Y G R O W T H D R I V E R S A N D T R A N S F O R M E D P O R T F O L I O GROWTH DRIVERS: PROVEN SUCCESS 23 (1) Pro forma for the acquisition of Avient Protective Materials (APM) COMPOSITES $51 $84 $212 $668 2016 2018 2020 2022 Long Term Growth Rate 10% Organic CAGR 10% HEALTHCARE $108 $113 $231 $293 2016 2018 2020 2022 Long Term Growth Rate 8-10% Organic CAGR 11% ASIA/EMERGING REGIONS $265 $358 $726 $830 2016 2018 2020 2022 Long Term Growth Rate 5% Organic CAGR 12% $340 $455 $790 2016 2018 2020 2022 $1,175 SUSTAINABLE SOLUTIONS Long Term Growth Rate 8-12% Organic CAGR 11% (1) (1)(1) (Sales in $ millions) #1 Color Formulator Dyneema® - World’s Strongest Fiber™ #1 in Composites applications for outdoor high performance #1 in Performance Inks Customized solutions 140+ PhDs on staff Rapid development of innovative products Extensive patent (2,500+) portfolio 33% Vitality Index Better-positioned toward stable, high-growth end markets Consumer, packaging, healthcare and defense comprise nearly 60% of sales Agnostic to raw materials, helping all customers achieve their goals Broad portfolio of diversified sustainable solutions 90%+ of our innovation pipeline invested in sustainable solutions Long-term growth rate well above GDP with expectations of 8-12% LEVERAGING OUR TRANSFORMED PORTFOLIO 24 Healthcare 8% Packaging 24% Consumer 20% Building & Construction 10% Industrial 15% Transportation 9% Energy 4% Telecom. 4% 2022 PF $3.65B sales Defense 6% Leading Positions Sustainable SolutionsDiversified IndustriesSpecialty Formulator (1) 2022 Pro forma for the acquisition of Avient Protective Materials (2) 2020 Pro forma for the acquisition of Clariant Color (1)(2) (1) $340M $455M $790M 2016 2018 2020PF 2022PF $1,175M P EE R C O M PAR IS O N S AVIENT IS ASSET LIGHT Capex / Revenue 2023E (%) Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of February 13, 2023 Note: Avient reflects 2023 estimated revenue of $3,450 and estimated run-rate CAPEX of $110M. 27 3 2 3 3 4 4 3 4 5 5 5 6 7 7 A vi en t K W R P P G F U L A V Y R P M F M C H U N H X L C E E C L A S H S C L E M N FREE CASH FLOW CONVERSION Source: Peer data per Bloomberg as of February 13, 2023 Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 28 79 87 81 79 76 73 90 77 76 75 73 64 59 33 A vi en t K W R P P G F U L A V Y R P M F M C C E A S H H X L E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of February 13, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 29 EV / 2023E EBITDA Historic Multiple 6.5 8.3 10.0 15.6 13.9 13.7 12.8 9.5 18.0 17.5 12.3 10.2 9.7 8.8 8.4 5.9 A vi en t (2 01 1) A vi en t (2 01 8) A vi en t K W R P P G R P M A V Y F U L H X L E C L F M C A S H S C L H U N E M N C E SEGMENT DATA U.S. & Canada 40% EMEA 37% Asia 18% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 20% Packaging 24% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE (1) Total company adjusted EBITDA of $592M includes corporate costs $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) Transportation 9% Healthcare 8% 31 C O L O R , A D D I T I V E S & I N K S 2022 REVENUE | $2 .4 B ILL ION US & Canada 34% EMEA 38% Asia 20% Latin America 8% END MARKET REGION 32 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 2% S P E C I A LT Y E N G I N E E R E D M AT E R I A L S 2022 PRO FORMA REVENUE | $1 .3 B ILL ION END MARKET US & Canada 52% EMEA 35% Asia 13% REGION 33 Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% Packaging 32% Consumer 27% Healthcare 8% Industrial 14% Building & Construction 5% Telecommunications 3% Energy 1% Defense 1% Asia (18% of sales) Transportation 9% 2022 PROFORMA AVIENT REGIONAL SALES BY END MARKET Packaging 27% Consumer 14% Healthcare 5% Industrial 17% Building & Construction 10% Energy 5% Defense 8% EMEA (37% of sales)Transportation 11% Packaging 13% Consumer 24% Healthcare 12% Industrial 15% Building & Construction 13% Energy 5% Defense 5% US & Canada (40% of sales) Transportation 7% Packaging 56% Consumer 23% Healthcare 4% Industrial 7% Building & Construction 4% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3% Telecommunications 6% 34 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

WIRE & CABLE OEM P V D F E X T R U S I O N • Improve extrusion line speed • Minimize defects, optimize coefficient of friction (CoF), control extrusion pressure, and eliminate die drool • Prevent melt fracture (sharkskin) • Reduce energy use in processing to achieve cost savings • Delivered a polyvinylidene fluoride (PVDF) solution that improved extrusion production times • Provided application specialists with deep knowledge of PVDF processing windows (melt and degradation temperatures) to help boost overall processing performance • Enhanced surface aesthetics by reducing friction and improving flow stability • Gained a reduction in energy use and offered added savings for other PVDF applications such as wire jacketing or tube and pipe extrusion Colorant Chromatics PVDF Processing Aid KEY REQUIREMENTS WHY AVIENT?

WALL PARTITION MANUFACTURER F O O D P R O C E S S I N G E N V I R O N M E N T S • Decrease growth of microbes on plastic surfaces that come in contact with food products • Compatibility with sheet extrusion processing • Maintain all other functional attributes inherent to product, such as ROHS, flame retardant standards, and specific brand color • Seamlessly incorporated multifunctional additives for optimal performance in reducing microbe growth • Developed custom formulation for complex processing configurations in sheet extrusion technology • Provided expertise in antimicrobial performance, chemical resistance, flame retardance, and regulatory product stewardship Cesa™ WithStand™ Antimicrobial Additives and Smartbatch™ Combination Colorants and Additives KEY REQUIREMENTS WHY AVIENT?

Excelite OnePager Grab Handle (2) TIER 1 MOLDER A U T O M O T I V E G R A B H A N D L E • Reduce production cycle times • Achieve processing consistency in chemical foaming additive (CFA) performance • Control dimensional stability and reduce production scrap rates • Lower conversion costs • Improved cycle time by 20% • Achieved additional 2% density reduction • Resulted in a finer cell structure with a higher cell density, significantly improving dispersion and dimensional stability • Maintained Class A finish • Reduced CFA use rate by 80% Excelite™ IM Chemical Foaming Additives KEY REQUIREMENTS* WHY AVIENT?

DIAGNOSTICS MANUFACTURER C O V I D - 1 9 C O N T A I N M E N T T U B E S C R E W C A P S • Wide range of durometers with consistent raw materials • Processing consistencies across the durometer ranges for an easy transition between materials • Materials formulated without animal derivatives at a competitive cost • Offered a comprehensive range of solutions to accommodate specific application demands such as barrier, flexibility, and sealing performance • Provided materials manufactured in an ISO 13485 certified facility • Delivered a series of medical-grade TPEs that could be extruded and injection molded Versaflex™ HC 3810 Thermoplastic Elastomers KEY REQUIREMENTS WHY AVIENT?

LEARN MORE TIER 2 MOLDER P A N E L F O R C O N S T R U C T I O N V E H I C L E S • Transition from painting extruded sheet (3-5mm) to molded-in color for two different thermoplastics • UV stability • Good appearance for visible part • Expedited approved solution that delivered the appearance and performance of a painted part • Developed formulations for two materials- PMMA and ABS • Offered aluminum appearance and required UV stability SmartBatch™ FX for Paint Replacement KEY REQUIREMENTS WHY AVIENT?